A study indicates that some breast cancer patients who receive mastectomy and reconstruction may be at risk of persistent drug use following surgery.

by Marcus A. Banks

Doctors at cancer centers in states with record COVID-19 hospitalization rates reflect on how lessons from early in the pandemic are helping them care for patients during the current surge.

by Ashley P. Taylor

Socioeconomic factors and racism can lead to poorer health outcomes for Black Americans. Genetics may also be a factor behind increased mortality rates.

by Marci A. Landsmann

A study shows that a blood test for gastrointestinal tumor mutations gave results in a third of the time needed for solid tissue testing. Patients who received the blood test were more likely to enroll in clinical trials.

by Emma Yasinski

The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.

by Anna Azvolinsky

Patient advocates with metastatic breast cancer argue that dosing of treatments for their disease should be more personalized and take into account quality of life.

by Marcus A. Banks

Facts and Stats

The advent of checkpoint inhibitors has broadened the range of cancer patients able to take advantage of immunotherapy.

by Bradley Jones

Advances in precision medicine and immunotherapy have led to better treatments for many patients with advanced lung cancer. But having a wider selection of therapies to choose from can make treatments more complex.

by Kendall K. Morgan

Forward Look

The Clinical Treatment Act aims to include more Medicaid recipients.

by Jen Tota McGivney

From the Editor-in-Chief

Paying attention to the social determinants of health will promote greater equity in cancer outcomes for all.

by William G. Nelson, MD, PhD